Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials.

OBJECTIVE To review the existing human controlled intervention studies of vitamin D as adjunctive therapy in settings of infection and provide recommendations for design and implementation of future studies in this field on the basis of the evidence reviewed. METHODS We conducted a systematic review of randomized controlled clinical trials that studied vitamin D for treatment or prevention of infectious diseases in humans. Studies from 1948 through 2009 were identified through search terms in PubMed and Ovid MEDLINE. RESULTS Thirteen published controlled trials were identified by our search criteria. Ten trials were placebo controlled, and 9 of the 10 were conducted in a rigorous double-blind design. The selected clinical trials demonstrated substantial heterogeneity in baseline patient demographics, sample size, and vitamin D intervention strategies. Serious adverse events attributable to vitamin D supplementation were rare across all studies. On the basis of studies reviewed to date, the strongest evidence supports further research into adjunctive vitamin D therapy for tuberculosis, influenza, and viral upper respiratory tract illnesses. In the selected studies, certain aspects of study design are highlighted to help guide future clinical research in the field. CONCLUSION More rigorously designed clinical trials are needed for further evaluation of the relationship between vitamin D status and the immune response to infection as well as for delineation of necessary changes in clinical practice and medical care of patients with vitamin D deficiency in infectious disease settings.

[1]  M. Sodemann,et al.  Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. , 2009, American journal of respiratory and critical care medicine.

[2]  B. Cunha,et al.  A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections , 2009, Epidemiology and Infection.

[3]  G. Robbins,et al.  High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. , 2009, AIDS research and human retroviruses.

[4]  E. Shane,et al.  Effect of Bimonthly Supplementation With Oral Cholecalciferol on Serum 25-Hydroxyvitamin D Concentrations in HIV-Infected Children and Adolescents , 2009, Pediatrics.

[5]  D. McMahon,et al.  Arpadi SM, McMahon D, Abrams EJ. Effect of Bimonthly Supplementation With Oral Cholecalciferol on Serum 25- Hydroxyvitamin D Concentrations in HIV-Infected Children and Adolescents. PEDIATRICS 2009;123(1):e121-e126 , 2009 .

[6]  D. Bruce,et al.  The paradoxical effects of vitamin D on type 1 mediated immunity. , 2008, Molecular aspects of medicine.

[7]  F. Sweep,et al.  Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. , 2008, AIDS research and human retroviruses.

[8]  E. Baldassarre,et al.  Koplik spots in a measles-vaccinated child. , 2008, The Pediatric infectious disease journal.

[9]  W. Grant Variations in vitamin D production could possibly explain the seasonality of childhood respiratory infections in Hawaii. , 2008, The Pediatric infectious disease journal.

[10]  L. Romani Cell mediated immunity to fungi: a reassessment. , 2008, Medical mycology.

[11]  W. Fawzi,et al.  A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. , 2008, The Journal of infectious diseases.

[12]  Judith E. Allen,et al.  Mapping immune response profiles: The emerging scenario from helminth immunology , 2007, European journal of immunology.

[13]  J. Aloia,et al.  Re: epidemic influenza and vitamin D. , 2007, Epidemiology and infection.

[14]  A. Avenell,et al.  Vitamin D supplementation to prevent infections: a sub-study of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). , 2007, Age and ageing.

[15]  M. Holick Vitamin D deficiency. , 2007, The New England journal of medicine.

[16]  Robert J Wilkinson,et al.  A single dose of vitamin D enhances immunity to mycobacteria. , 2007, American journal of respiratory and critical care medicine.

[17]  J. Söderlund,et al.  The antimicrobial peptide LL-37 inhibits HIV-1 replication. , 2007, Current HIV research.

[18]  A. Bayat,et al.  Genetic susceptibility to total hip arthroplasty failure: a preliminary study on the influence of matrix metalloproteinase 1, interleukin 6 polymorphisms and vitamin D receptor , 2007, Annals of the rheumatic diseases.

[19]  R. Wilkinson,et al.  Vitamin D in the treatment of pulmonary tuberculosis , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  Sumita Sinha,et al.  Seasonal variation in the epidemiology of sepsis* , 2007, Critical care medicine.

[21]  J. Wehkamp,et al.  Defensins and cathelicidins in gastrointestinal infections , 2007, Current opinion in gastroenterology.

[22]  S. Madronich,et al.  Epidemic influenza and vitamin D , 2006, Epidemiology and Infection.

[23]  M. Holick,et al.  Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. , 2006, Anticancer research.

[24]  N. Range,et al.  The effect of multi-vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two-by-two factorial trial in Mwanza, Tanzania. , 2006, The British journal of nutrition.

[25]  J. Adams,et al.  Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response , 2006, Science.

[26]  John Robbins,et al.  Calcium plus vitamin D supplementation and the risk of colorectal cancer. , 2006, The New England journal of medicine.

[27]  E. Takeda,et al.  Inhibitory Effect of Long Term 1.ALPHA.-Hydroxyvitamin D3 Administration on Helicobacter pylori Infection , 2006 .

[28]  C. Rumende,et al.  The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. , 2006, Acta medica Indonesiana.

[29]  J. Aloia,et al.  A randomized controlled trial of vitamin D3 supplementation in African American women. , 2005, Archives of internal medicine.

[30]  C. Cooper,et al.  Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial , 2005, The Lancet.

[31]  R. Bals,et al.  Antimicrobial peptides in lung inflammation. , 2005, Chemical immunology and allergy.

[32]  M. Cantorna,et al.  Mounting Evidence for Vitamin D as an Environmental Factor Affecting Autoimmune Disease Prevalence , 2004, Experimental biology and medicine.

[33]  Hidekazu Nishimura,et al.  Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus , 2004, Nature.

[34]  Mark A. Miller,et al.  Influenza and the winter increase in mortality in the United States, 1959-1999. , 2004, American journal of epidemiology.

[35]  John H. White,et al.  Cutting Edge: 1,25-Dihydroxyvitamin D3 Is a Direct Inducer of Antimicrobial Peptide Gene Expression1 , 2004, The Journal of Immunology.

[36]  M. Shinohara,et al.  Vitamin D receptor gene polymorphism is associated with chronic periodontitis. , 2003, Life sciences.

[37]  Y. Guan,et al.  Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? , 2002, The Lancet.

[38]  Balaji Ramanathan,et al.  Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity. , 2002, Microbes and infection.

[39]  W. Ambrosius,et al.  A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  N. Reiner,et al.  1α,25-Dihydroxyvitamin D3-induced Monocyte Antimycobacterial Activity Is Regulated by Phosphatidylinositol 3-Kinase and Mediated by the NADPH-dependent Phagocyte Oxidase* , 2001, The Journal of Biological Chemistry.

[41]  R. Hunter,et al.  Relationship of survival, organism containment, and granuloma formation in acute murine tuberculosis. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[42]  M. Frye,et al.  Epithelial defensins impair adenoviral infection: implication for adenovirus-mediated gene therapy. , 1999, Human gene therapy.

[43]  J. Kriesel,et al.  Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. , 1999, Vaccine.

[44]  A. Gabr,et al.  Vitamin D administration to tuberculous children and its value. , 1998, Bollettino chimico farmaceutico.

[45]  K. Sommers,et al.  Effects of calcitriol on eosinophil activity and antibody responses in patients with schistosomiasis , 1997, European Journal of Clinical Pharmacology.

[46]  S. Frøland,et al.  Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. , 1994, The Journal of infectious diseases.

[47]  Ganguly Nk,et al.  Sub-clinical rickets and recurrent infection. , 1994 .

[48]  P. Rehman Sub-clinical rickets and recurrent infection. , 1994, Journal of tropical pediatrics.

[49]  K. Simon,et al.  Effect of 1,25-dihydroxyvitamin D3 and its analogs on human immunodeficiency virus infection in monocytes/macrophages. , 1993, Leukemia.

[50]  R. Connor,et al.  1α,25-Dihydroxyvitamin D3 inhibits productive infection of human monocytes by HIV-1 , 1991 .

[51]  R. Connor,et al.  1 alpha,25-dihydroxyvitamin D3 inhibits productive infection of human monocytes by HIV-1. , 1991, Biochemical and biophysical research communications.

[52]  J. Horgan Space invaders. Extra! Extra! Flu linked to sunspots! , 1990, Scientific American.

[53]  J. Searle,et al.  Is the brain's mind a computer program? , 1990, Scientific American.

[54]  J. Hamilton,et al.  Hepatitis B vaccines in patients with chronic renal failure before dialysis. , 1988, The Journal of infectious diseases.

[55]  A. J. Crowle,et al.  Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages , 1987, Infection and immunity.

[56]  G. Rook,et al.  Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. , 1986, Immunology.

[57]  S. Krane,et al.  Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. , 1983, The Journal of clinical endocrinology and metabolism.

[58]  H. DeLuca,et al.  Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. , 1979, Science.

[59]  G. Amirhakimi,et al.  The rachitic lung. Pulmonary findings in 30 infants and children with malnutritional rickets. , 1977, Clinical pediatrics.

[60]  H. Box Observations upon Lixophaga diatraeae , Townsend, a Tachinid Parasite of Diatraea saccharalis , Fabr., in Porto Rico , 1928 .